BiotechDueDiligence - Legacy Features
The features and elements of the BiotechDueDiligence website highlighted on this page are not currently supported, but are maintained for archival and reference purposes.
If this is a mistake and any of these features should be revived (or more notably if you are interested in helping to maintain them!), please let me know.
If this is a mistake and any of these features should be revived (or more notably if you are interested in helping to maintain them!), please let me know.
- Biotech Stock Research Notes - the birthplace and namesake of BDD, featuring detailed notes, links, resources for select small- and mid-cap biotech companies
- Investor Relations Q&A - your starting point for due diligence on dozens on biotech stocks
- Archive - biotech calendar with links to blog posts (e.g., conference call / webcast notes, scientific meeting presentations)
- Partnerships - keeping track of the tangled web of deals, terms (royalties, milestones, etc.), and progress
- Biotech Initial Public Offerings - links to prospectuses (SEC form S-1) and other information related to IPOs
Past Contributors - Thanks to those below for helping make the site better for all
Duncan Emerton
Dr. Duncan Emerton (on Twitter @biosimilarz) is the go-to source for news, discussion and analysis of the world of biosimilars product development. Check out his dedicated Biosimilarz website. Here at BiotechDueDiligence, check out his podcasts and guest blog posts.
Mike O'Neill
Mike is a seasoned biotech investor that contributes the newest feature on the website: "Investor Relations Questions." Check out the IRQ page for an index of responses on financial and fundamental topics critical to all biotech stocks, and follow Mike on Twitter @MikeOinSATX.
Jake Schaible
Jake is a veteran of the biopharma industry with over two decades of corporate development experience, directly for companies like Ligand, Lilly & GenVec, as well as many others via his business development and competitive intelligence consulting practice. Founder and CEO of several startups. Former chair of the Healthcare Sector for the Licensing Executive Society. Jake is also an active investor in both emerging public and private biopharma. Biochemist by training who got his MBA to escape the lab, he’s always on the hunt for small biotech with interesting concepts to address unmet medical needs seeking funding or advice on partnering. Follow him on Twitter @jjschaible or via LinkedIn.
Derek DiRocco
Derek is a post-doctoral fellow at Harvard Medical School and an enthusiastic observer and scholar of the biotech industry. In addition to his contributions, please check out his DPD Research blog and follow him on Twitter @DPDResearch.
Dale Yuzuki
Dale is currently a marketing professional for a large life sciences corporation and an expert in the next-generation sequencing and genomics landscape. Check out all of his writing on his Next Generation Technologist blog and follow Dale on Twitter @DaleYuzuki.
Daniel Low
Daniel is an individual investor who is always on top of the latest news related to Complete Genomics. Follow him on Twitter @ddlow.
Dr. Duncan Emerton (on Twitter @biosimilarz) is the go-to source for news, discussion and analysis of the world of biosimilars product development. Check out his dedicated Biosimilarz website. Here at BiotechDueDiligence, check out his podcasts and guest blog posts.
Mike O'Neill
Mike is a seasoned biotech investor that contributes the newest feature on the website: "Investor Relations Questions." Check out the IRQ page for an index of responses on financial and fundamental topics critical to all biotech stocks, and follow Mike on Twitter @MikeOinSATX.
Jake Schaible
Jake is a veteran of the biopharma industry with over two decades of corporate development experience, directly for companies like Ligand, Lilly & GenVec, as well as many others via his business development and competitive intelligence consulting practice. Founder and CEO of several startups. Former chair of the Healthcare Sector for the Licensing Executive Society. Jake is also an active investor in both emerging public and private biopharma. Biochemist by training who got his MBA to escape the lab, he’s always on the hunt for small biotech with interesting concepts to address unmet medical needs seeking funding or advice on partnering. Follow him on Twitter @jjschaible or via LinkedIn.
Derek DiRocco
Derek is a post-doctoral fellow at Harvard Medical School and an enthusiastic observer and scholar of the biotech industry. In addition to his contributions, please check out his DPD Research blog and follow him on Twitter @DPDResearch.
Dale Yuzuki
Dale is currently a marketing professional for a large life sciences corporation and an expert in the next-generation sequencing and genomics landscape. Check out all of his writing on his Next Generation Technologist blog and follow Dale on Twitter @DaleYuzuki.
Daniel Low
Daniel is an individual investor who is always on top of the latest news related to Complete Genomics. Follow him on Twitter @ddlow.